LU92446I2 - Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium - Google Patents

Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium

Info

Publication number
LU92446I2
LU92446I2 LU92446C LU92446C LU92446I2 LU 92446 I2 LU92446 I2 LU 92446I2 LU 92446 C LU92446 C LU 92446C LU 92446 C LU92446 C LU 92446C LU 92446 I2 LU92446 I2 LU 92446I2
Authority
LU
Luxembourg
Prior art keywords
dolutegravir
solvate
pharmaceutically acceptable
acceptable salt
including sodium
Prior art date
Application number
LU92446C
Other languages
English (en)
Original Assignee
Shionogi & Co
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37215098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92446(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi & Co, Viiv Healthcare Co filed Critical Shionogi & Co
Publication of LU92446I2 publication Critical patent/LU92446I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LU92446C 2005-04-28 2014-05-07 Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium LU92446I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005131161 2005-04-28
JP2005312076 2005-10-27
PCT/US2006/016604 WO2006116764A1 (fr) 2005-04-28 2006-04-28 Derive polycyclique de la carbamoylpyridone a activite inhibitrice sur l'integrase du vih

Publications (1)

Publication Number Publication Date
LU92446I2 true LU92446I2 (fr) 2015-10-29

Family

ID=37215098

Family Applications (2)

Application Number Title Priority Date Filing Date
LU92446C LU92446I2 (fr) 2005-04-28 2014-05-07 Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium
LU00210C LUC00210I2 (fr) 2005-04-28 2021-06-15

Family Applications After (1)

Application Number Title Priority Date Filing Date
LU00210C LUC00210I2 (fr) 2005-04-28 2021-06-15

Country Status (29)

Country Link
US (21) US8129385B2 (fr)
EP (9) EP3187226A1 (fr)
JP (2) JP4295353B2 (fr)
KR (4) KR101363875B1 (fr)
AU (1) AU2006239177B8 (fr)
BR (1) BRPI0610030B8 (fr)
CA (1) CA2606282C (fr)
CY (6) CY1115151T1 (fr)
DK (6) DK3284520T3 (fr)
EA (1) EA014162B1 (fr)
ES (7) ES2667868T5 (fr)
FI (1) FIC20210017I1 (fr)
FR (1) FR14C0041I2 (fr)
HK (4) HK1107227A1 (fr)
HU (6) HUE037795T2 (fr)
IL (4) IL186555A (fr)
LT (4) LT3372281T (fr)
LU (2) LU92446I2 (fr)
MA (1) MA29460B1 (fr)
MX (2) MX302718B (fr)
NL (2) NL300676I2 (fr)
NO (5) NO339525B1 (fr)
NZ (1) NZ562339A (fr)
PL (5) PL3372281T3 (fr)
PT (5) PT3372281T (fr)
SI (6) SI3045206T1 (fr)
TW (1) TWI378931B (fr)
VN (1) VN34404A1 (fr)
WO (1) WO2006116764A1 (fr)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2287167A1 (fr) 2003-12-24 2011-02-23 Biota Scientific Management Pty. Ltd. Agents polycycliques pour le traitement des infections de virus respiratoire syncytial
US7273859B2 (en) * 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
SI3045206T1 (en) 2005-04-28 2018-07-31 Viiv Healthcare Company A polycyclic carbamoylpyridone derivative with inhibitory activity for the HIV integrase
CA2607151C (fr) 2005-05-10 2012-06-19 Merck & Co., Inc. Inhibiteurs de l'integrase du vih
ATE517899T1 (de) 2005-10-04 2011-08-15 Angeletti P Ist Richerche Bio Hiv-integrasehemmer
BRPI0617842A2 (pt) 2005-10-27 2011-08-09 Shionogi & Co composto ou um sal farmaceuticamente aceitável ou um solvato do mesmo, e, composição farmacêutica
TWI423972B (zh) 2006-09-28 2014-01-21 Biota Scient Management 治療呼吸系融合細胞病毒感染之多環劑
JP5269085B2 (ja) * 2007-11-15 2013-08-21 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルス複製のインヒビター
PT2220076E (pt) 2007-11-15 2012-04-26 Gilead Sciences Inc Inibidores da replicação do vírus da imunodeficiência humana
WO2009062285A1 (fr) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibiteurs de la réplication du virus de l'immunodéficience humaine
ES2449752T3 (es) * 2008-07-25 2014-03-21 Viiv Healthcare Company Proceso para la preparación de un derivado de pirido[1,2-a]pirrolo[1',2':3,4]imidazo[1,2-d]piracin-8-carboxamida
PT2660239T (pt) * 2008-07-25 2017-02-24 Shionogi & Co Compostos químicos como intermediários sintéticos
WO2010011815A1 (fr) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Composés chimiques
WO2010011818A1 (fr) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Composés chimiques
EP2320908B9 (fr) * 2008-07-25 2014-06-18 VIIV Healthcare Company Prodrugs de dolutegravir
AU2014277831C1 (en) * 2008-12-11 2022-10-06 Shionogi & Co. Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
US8710249B2 (en) 2008-12-11 2014-04-29 Shionogi & Co., Ltd. Maltol ether processes and intermediates
CN102245182B (zh) * 2008-12-11 2014-07-23 盐野义制药株式会社 氨基甲酰基吡啶酮hiv整合酶抑制剂和中间体的合成
CN106986823A (zh) 2008-12-11 2017-07-28 盐野义制药株式会社 氨甲酰基吡啶酮hiv整合酶抑制剂的方法和中间体
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
US8927710B2 (en) 2009-06-15 2015-01-06 Shionogi & Co., Ltd. Substituted polycyclic carbamoylpyridone derivative
WO2011011483A1 (fr) * 2009-07-22 2011-01-27 Glaxosmithkline Llc Composés chimiques
EP2488521B1 (fr) 2009-10-13 2013-12-18 Elanco Animal Health Ireland Limited Inhibiteurs de l'intégrase macrocyclique
AU2014202404C1 (en) * 2010-01-27 2022-06-23 Viiv Healthcare Company Antiviral therapy
AU2014202406C1 (en) * 2010-01-27 2019-03-07 Viiv Healthcare Company Antiviral therapy
ES2670811T3 (es) 2010-01-27 2018-06-01 Viiv Healthcare Company Terapia antivírica
TWI508968B (zh) * 2010-02-08 2015-11-21 Biota Scient Management 用於治療呼吸道融合性病毒感染的化合物
EP2540720B1 (fr) * 2010-02-26 2015-04-15 Japan Tobacco, Inc. Dérivé de 1,3,4,8-tétrahydro-2h-pyrido[1,2-a]pyrazine et son utilisation comme inhibiteur d'intégrase de vih
TWI582097B (zh) * 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
JP5739517B2 (ja) 2010-04-02 2015-06-24 ヤンセン・アールアンドデイ・アイルランド 大環状インテグラーゼ阻害剤
WO2011129095A1 (fr) * 2010-04-12 2011-10-20 塩野義製薬株式会社 Dérivé de pyridone ayant une activité inhibitrice de l'intégrase
US9073941B2 (en) 2010-06-28 2015-07-07 Academia Sinica Compounds and methods for treating tuberculosis infection
HUE054473T2 (hu) 2010-08-05 2021-09-28 Shionogi & Co Eljárás HIV-integráz inhibitor hatású vegyületek elõállítására
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
MX2013003139A (es) * 2010-09-24 2013-06-18 Shionogi & Co Profarmaco de derivado de carbamoilpiridona policiclica substituida.
US8796303B2 (en) 2010-11-26 2014-08-05 Biota Scientific Management Pty Ltd. Imidazo[2,1-G][1,7]naphthyridines for treating respiratory syncytial virus infections
US20140213553A1 (en) * 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
US9206197B2 (en) 2011-09-14 2015-12-08 Mapi Pharma Ltd. Amorphous form of dolutegravir
CN103974957A (zh) * 2011-10-12 2014-08-06 盐野义制药株式会社 具有整合酶抑制活性的多环吡啶酮衍生物
EP2797597B1 (fr) 2011-12-28 2020-02-26 Global Blood Therapeutics, Inc. Composés d'aldéhydes hétéroaryles substitués et leurs procédés d'utilisation dans l'accroissement de l'oxygénation tissulaire
LT3141542T (lt) 2011-12-28 2020-09-25 Global Blood Therapeutics, Inc. Pakeistieji benzaldehido junginiai ir jų panaudojimas didinant audinių aprūpinimą deguonimi
EP2931730B1 (fr) * 2012-12-17 2019-08-07 Merck Sharp & Dohme Corp. Dérivés 4-pyridinonetriazines en tant qu'inhibiteurs de l'intégrase du vih
MY164352A (en) 2012-12-21 2017-12-15 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
MX2015008467A (es) * 2012-12-27 2015-09-23 Japan Tobacco Inc Derivado sustituido de espiropirido[1,2-a]pirazina y uso medico del mismo como inhibidor de la integrasa del virus de inmunodeficiencia humana.
EP2767272A1 (fr) 2013-02-18 2014-08-20 Ratiopharm GmbH Forme posologique pharmaceutique solide de dolutegravir
EP2956123A1 (fr) 2013-02-18 2015-12-23 ratiopharm GmbH Forme galénique pharmaceutique solide de dolutegravir
US9573965B2 (en) 2013-02-19 2017-02-21 Aurobindo Pharma Ltd Process for the preparation of Dolutegravir
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
SG10201802911RA (en) 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
PE20160078A1 (es) 2013-03-15 2016-03-02 Global Blood Therapeutics Inc Compuestos y sus usos para modular la hemoglobina
WO2014145040A1 (fr) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Composés aldéhydes substitués et leurs procédés d'utilisation pour accroître l'oxygénation tissulaire
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
SG11201507349TA (en) 2013-03-15 2015-10-29 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP2986291B1 (fr) 2013-04-16 2020-05-27 Merck Sharp & Dohme Corp. Composés dérivés de 4-pyridone et leurs utilisations en tant qu'inhibiteurs de la vih intégrase
US9951079B2 (en) * 2013-06-13 2018-04-24 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
WO2015001572A2 (fr) * 2013-07-04 2015-01-08 Hetero Research Foundation Procédé pour la préparation d'intermédiaire de dolutégravir
PL3252058T3 (pl) * 2013-07-12 2021-07-19 Gilead Sciences, Inc. Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv
NO2865735T3 (fr) 2013-07-12 2018-07-21
WO2015009927A1 (fr) 2013-07-17 2015-01-22 Ratiopharm Gmbh Sels de dolutégravir
WO2015019310A1 (fr) 2013-08-07 2015-02-12 Mylan Laboratories Ltd Procédé de préparation de dolutégravir et ses intermédiaires
WO2015039348A1 (fr) * 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques utiles comme inhibiteurs de l'intégrase du vih
SG11201602217XA (en) * 2013-09-27 2016-04-28 Merck Sharp & Dohme Substituted quinolizine derivatives useful as hiv integrase inhibitors
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015089847A1 (fr) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Composés à hétérocycles spirocycliques utiles en tant qu'inhibiteurs d'intégrase du vih
WO2015092752A1 (fr) 2013-12-20 2015-06-25 Mylan Laboratories Ltd. Nouvelle forme cristalline de dolutegravir sodium
WO2015108945A2 (fr) 2014-01-14 2015-07-23 Board Of Regents Of The University Of Nebraska Compositions et méthodes pour l'administration d'agents thérapeutiques
EP3096763B1 (fr) 2014-01-21 2019-12-25 Laurus Labs Limited Nouveau procédé de préparation de dolutégravir et de ses sels pharmaceutiquement acceptables
SG10201804139VA (en) 2014-02-07 2018-06-28 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
CN107056813B (zh) * 2014-03-19 2019-07-30 杭州普晒医药科技有限公司 德罗格韦钠盐的晶型及其制备方法
WO2015140569A1 (fr) 2014-03-20 2015-09-24 Cipla Limited Composition pharmaceutique
ZA201503540B (en) * 2014-05-20 2016-10-26 Cipla Ltd Process for preparing polycyclic carbamoyl pyridone derivatives
TWI677489B (zh) * 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (fr) 2014-06-20 2018-06-23
WO2016027879A1 (fr) * 2014-08-22 2016-02-25 塩野義製薬株式会社 Dérivé de pyridone polycyclique possédant une activité inhibitrice d'intégrase
US11311545B2 (en) 2014-10-09 2022-04-26 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
WO2016092527A1 (fr) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited Procédé de préparation de dolutégravir
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
WO2016102078A1 (fr) 2014-12-24 2016-06-30 Ratiopharm Gmbh Formes solides de dolutégravir sodique
EP3045461A1 (fr) 2015-01-16 2016-07-20 LEK Pharmaceuticals d.d. Procédés de préparation de Dolutégravir et de ses analogues
CN107531614B (zh) 2015-02-06 2020-04-10 迈兰实验室有限公司 德罗格韦的制备方法
CZ201599A3 (cs) 2015-02-13 2016-08-24 Zentiva, K.S. Pevné formy solí dolutegraviru a způsob jejich přípravy
EP3285582B1 (fr) * 2015-03-26 2020-11-11 Merck Sharp & Dohme Corp. Dérivés de quinolizine substitués par un phosphate utiles en tant qu'inhibiteurs de l'intégrase du vih
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
CN107531727B (zh) * 2015-04-02 2019-11-29 吉利德科学公司 多环氨甲酰基吡啶酮化合物及其药物用途
DK3428170T3 (da) * 2015-04-28 2021-03-01 Shionogi & Co Anti-influenza polycyklisk pyridonderivat og prodrug deraf
WO2016187788A1 (fr) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Composés hétérocycliques tricycliques fusionnés utiles pour traiter l'infection au vih
CZ2015537A3 (cs) 2015-08-04 2017-02-15 Zentiva, K.S. Pevné formy amorfního dolutegraviru
ES2969437T3 (es) 2015-08-19 2024-05-20 Laurus Labs Ltd Polimorfos novedosos de dolutegravir y de sales del mismo
TW202220660A (zh) 2015-11-09 2022-06-01 美商基利科學股份有限公司 用於治療人類免疫缺乏病毒之治療組合物
WO2017087257A1 (fr) 2015-11-17 2017-05-26 Merck Sharp & Dohme Corp. Dérivés de pyridotriazine amido-substitués utiles en tant qu'inhibiteurs de l'intégrase du vih
MX2018006832A (es) 2015-12-04 2018-11-09 Global Blood Therapeutics Inc Regimenes de dosificacion de 2-hidroxi-6-((2-(1-isopropil-1h-piraz ol-5-il)-piridin-3-il)-metoxi)-benzaldehido.
EP3389380B1 (fr) 2015-12-15 2021-07-21 Merck Sharp & Dohme Corp. Dérivés de quinolizine spirocycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
WO2017109649A1 (fr) 2015-12-21 2017-06-29 Lupin Limited Procédé de préparation d'inhibiteurs de l'intégrase du vih
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
WO2017208105A1 (fr) 2016-05-30 2017-12-07 Lupin Limited Nouvelle forme cristalline de dolutégravir sodique
WO2017223280A2 (fr) * 2016-06-23 2017-12-28 Viiv Healthcare Company Compositions et méthodes de libération d'agents thérapeutiques
US11045423B2 (en) 2016-08-08 2021-06-29 Hetero Labs Limited Anti-retroviral compositions
ES2952878T3 (es) 2016-08-08 2023-11-06 Hetero Labs Ltd Una composición antirretroviral multiclase
CA3033667A1 (fr) * 2016-08-12 2018-02-15 Nanjing Gator Meditech Company, Ltd. Regulateurs de proteine kinases
WO2018042332A1 (fr) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinaisons, utilisations et traitements correspondants
WO2018057408A1 (fr) * 2016-09-21 2018-03-29 Merck Sharp & Dohme Corp. Système d'administration de médicaments pour l'administration d'inhibiteurs de l'intégrase
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
RU2749043C2 (ru) 2016-12-02 2021-06-03 Мерк Шарп И Доум Корп. Трициклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич
JOP20190130A1 (ar) * 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
WO2018109786A1 (fr) 2016-12-16 2018-06-21 Cipla Limited Nouveaux polymorphes et sels de dérivés de carbamoyle pyridone polycycliques
WO2018140368A1 (fr) 2017-01-26 2018-08-02 Merck Sharp & Dohme Corp. Dérivés de quinolizine substitués utiles en tant qu'inhibiteurs de l'intégrase du vih
MX2019009810A (es) 2017-02-16 2019-12-02 Sandoz Ag Formas cristalinas de cabotegravir de sodio.
EP3363802B1 (fr) * 2017-02-16 2019-11-20 Sandoz AG Forme cristalline du sel de sodium de cabotegravir
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
US11564921B2 (en) 2017-07-21 2023-01-31 Viiv Healthcare Company Regimens for treating HIV infections and AIDS
US20210040116A1 (en) 2017-09-07 2021-02-11 Cipla Limited New Polymorphs of Dolutegravir Sodium
CN111386276B (zh) 2017-10-06 2023-06-23 盐野义制药株式会社 制备取代的多环吡啶酮衍生物的立体选择性方法
CA3126348A1 (fr) 2018-01-12 2020-07-18 Board Of Regents Of The University Of Nebraska Promedicaments antiviraux et formulations de ceux-ci
WO2019159199A1 (fr) 2018-02-16 2019-08-22 Cipla Limited Procédé à flux continu pour la préparation de dérivés de carbamoylpyridone polycycliques à ingrédients pharmaceutiquement actifs et intermédiaires de ceux-ci
CA3132832A1 (fr) 2018-04-09 2019-10-17 Howard E. Gendelman Promedicaments antiviraux et formulations de ceux-ci
CN110526930B (zh) 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
MX2020012176A (es) 2018-05-31 2021-01-29 Shionogi & Co Derivado policiclico de carbamoilpiridona.
PE20201414A1 (es) * 2018-05-31 2020-12-07 Shionogi & Co Derivado policiclico de piridona
TW202323254A (zh) * 2018-05-31 2023-06-16 日商鹽野義製藥股份有限公司 多環性吡啶并三𠯤衍生物
US11634431B2 (en) 2018-07-12 2023-04-25 Laurus Labs Limited Process for purification of protected polycyclic carbamoylpyridone derivatives
ES2966707T3 (es) 2018-10-01 2024-04-23 Global Blood Therapeutics Inc Moduladores de la hemoglobina para el tratamiento de la drepanocitosis
AU2019368247A1 (en) 2018-10-22 2021-06-03 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and nanoformulations thereof
MX2021011394A (es) 2019-03-22 2021-10-13 Gilead Sciences Inc Compuestos de carbamoilpiridona triciclica puenteada y su uso farmaceutico.
RU2717101C1 (ru) * 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
US20230059640A1 (en) 2019-11-28 2023-02-23 Shionogi & Co., Ltd. Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent
UY38982A (es) 2019-12-09 2021-06-30 Viiv Healthcare Co Composiciones farmacéuticas
WO2021173522A1 (fr) 2020-02-24 2021-09-02 Gilead Sciences, Inc. Composés tétracycliques pour le traitement d'une infection par le vih
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
JP2023539344A (ja) 2020-09-01 2023-09-13 ヴィーブ、ヘルスケア、カンパニー カボテグラビルおよびレボノルゲストレルの組合せ
WO2022079739A1 (fr) 2020-10-14 2022-04-21 Cipla Limited Compositions à dose fixe de cabotégravir et de rilpivirine
EP4255472A2 (fr) 2020-12-07 2023-10-11 VIIV Healthcare Company Polythérapie
LT4196479T (lt) 2021-01-19 2023-12-11 Gilead Sciences, Inc. Pakeistieji piridotriazino junginiai ir jų panaudojimo būdai
CN117715908A (zh) 2021-06-03 2024-03-15 江苏恒瑞医药股份有限公司 具有整合酶抑制活性的吡啶酮化合物及其药用用途
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
WO2023102374A1 (fr) 2021-12-03 2023-06-08 Viiv Healthcase Company Procédé de synthèse de (r)-3-aminobutan-1-ol

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959316A (en) * 1972-03-13 1976-05-25 Snam Progetti S.P.A. Procedure for propylene oxide synthesis
JPH0296506A (ja) * 1988-09-30 1990-04-09 Daicel Chem Ind Ltd 除草剤組成物
JP2533796B2 (ja) * 1988-10-18 1996-09-11 ダイセル化学工業株式会社 ５−アルコキシピリジン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
JP2551472B2 (ja) 1988-10-18 1996-11-06 ダイセル化学工業株式会社 ５−アルコキシ−γ−ピロン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
RU2220960C2 (ru) 1997-12-22 2004-01-10 Фармация Энд Апджон Компани 4-гидрокси-3-хинолинкарбоксамиды и гидразиды, фармацевтическая композиция и способ лечения на их основе
EP1297834A4 (fr) † 2000-06-14 2007-05-09 Shionogi & Co Inhibiteur d'enzymes possedant deux ions metal divalents en tant que centres actifs
US6580562B2 (en) 2000-07-24 2003-06-17 Yazaki Corporation On-vehicle display unit
US6384263B1 (en) 2000-08-04 2002-05-07 E. I. Du Pont De Nemours And Company Process for making 3-hydroxyalkanelnitriles and conversion of the 3-hydroxyalkanelnitrile to an hydroxyaminoalkane
JP4287649B2 (ja) 2000-10-12 2009-07-01 メルク エンド カムパニー インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類
JP2003032772A (ja) 2001-07-12 2003-01-31 Foster Electric Co Ltd 耳掛け式イヤホン
EP2266958B1 (fr) 2001-08-10 2017-03-15 Shionogi & Co., Ltd. Agent antiviral
ME00427B (me) 2001-10-26 2011-10-10 Msd Italia Srl N-supstituisani hidroksipiramidinon karboksamidni inhibitori hiv integraze
ATE355064T1 (de) 2001-10-26 2006-03-15 Angeletti P Ist Richerche Bio Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
EP1467970B1 (fr) 2002-01-17 2007-08-22 Merck & Co., Inc. Carboxamides hydroxynaphthyridinone utiles comme inhibiteurs de l'integrase du vih
AU2003248872A1 (en) 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Hiv integrase inhibitors
JP3908248B2 (ja) 2002-08-13 2007-04-25 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有するヘテロ環化合物
CA2498111A1 (fr) 2002-09-11 2004-03-25 Merck & Co., Inc. Composes de dihydroxypyridopyrazine-1,6-diones utiles en tant qu'inhibiteurs de l'integrase du vih
PL377354A1 (pl) 2002-12-27 2006-01-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetrahydro-4H-pirydo[1,2-a]pirymidyny i związki pokrewne użyteczne jako inhibitory integrazy HIV
US6960680B2 (en) 2003-01-08 2005-11-01 Rhodia Chirex, Inc. Manufacture of water-soluble β-hydroxynitriles
JP2004244320A (ja) 2003-02-10 2004-09-02 Shionogi & Co Ltd 含窒素複素環抗ウイルス剤
EP1622615A4 (fr) 2003-05-13 2009-02-18 Smithkline Beecham Corp Inihbiteurs de l'integrase de la naphtyridine
WO2005015927A1 (fr) * 2003-08-12 2005-02-17 Rachel Beijer Service de messages planifies
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
JP4530642B2 (ja) 2003-10-31 2010-08-25 オリンパス株式会社 内視鏡装置
RU2006128848A (ru) 2004-02-11 2008-03-20 СмитКлайн Бичем Корпорейшн (US) Ингибиторы вич-интегразы
CA2557785A1 (fr) 2004-03-09 2005-10-06 Merck & Co. Inc. Inhibiteurs de l'integrase du vih
JP2007528379A (ja) 2004-03-09 2007-10-11 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Ｈｉｖインテグラーゼ阻害薬
WO2005110414A2 (fr) 2004-05-07 2005-11-24 Merck & Co., Inc. Inhibiteurs de l'integrase du vih
WO2006066414A1 (fr) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones et procedes d’inhibition de l’integrase du vih
JP5317257B2 (ja) 2005-02-21 2013-10-16 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する２環性カルバモイルピリドン誘導体
JP5116660B2 (ja) 2005-03-31 2013-01-09 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Ｈｉｖインテグラーゼ阻害剤
SI3045206T1 (en) * 2005-04-28 2018-07-31 Viiv Healthcare Company A polycyclic carbamoylpyridone derivative with inhibitory activity for the HIV integrase
JP2005312076A (ja) 2005-05-26 2005-11-04 Olympus Corp 電子撮像装置
EP1910363A4 (fr) 2005-08-04 2010-05-26 Glaxosmithkline Llc Inhibiteurs de l'integrase du vih
BRPI0617842A2 (pt) 2005-10-27 2011-08-09 Shionogi & Co composto ou um sal farmaceuticamente aceitável ou um solvato do mesmo, e, composição farmacêutica

Also Published As

Publication number Publication date
NL300676I2 (fr) 2016-10-11
EP2527007A1 (fr) 2012-11-28
US20160137666A1 (en) 2016-05-19
CY1120345T1 (el) 2019-07-10
ES2437268T3 (es) 2014-01-09
HK1249742A1 (zh) 2018-11-09
EP3284519A1 (fr) 2018-02-21
ES2667868T3 (es) 2018-05-14
CA2606282A1 (fr) 2006-11-02
ES2567197T3 (es) 2016-04-20
AU2006239177B8 (en) 2012-02-16
US20160304535A1 (en) 2016-10-20
CY1122052T1 (el) 2020-10-14
DK3045206T3 (en) 2018-05-22
HK1107227A1 (en) 2008-04-03
US20170267693A1 (en) 2017-09-21
PL2465580T3 (pl) 2014-05-30
HUE037795T2 (hu) 2018-09-28
SI3372281T1 (sl) 2021-11-30
EP2527007B1 (fr) 2016-03-30
DK1874117T3 (da) 2013-09-23
EP3284520A1 (fr) 2018-02-21
US20140200209A1 (en) 2014-07-17
NL301109I2 (nl) 2021-09-15
PT3284520T (pt) 2019-09-10
US20170260203A1 (en) 2017-09-14
PL3284520T3 (pl) 2020-01-31
CY2014024I2 (el) 2015-12-09
EP2465580B1 (fr) 2013-12-18
LTC2465580I2 (fr) 2022-10-10
US20170145033A1 (en) 2017-05-25
EP3045206B2 (fr) 2023-02-15
DK2465580T3 (en) 2014-03-10
LTPA2021512I1 (fr) 2021-07-12
NO2023042I1 (no) 2023-11-08
SI3045206T1 (en) 2018-07-31
CY1124601T1 (el) 2022-07-22
NO20161315A1 (no) 2007-11-22
NZ562339A (en) 2011-01-28
EP1874117B1 (fr) 2013-08-28
LUC00210I2 (fr) 2022-10-07
KR101580310B1 (ko) 2016-01-04
VN34404A1 (en) 2013-07-25
EP3187226A1 (fr) 2017-07-05
TWI378931B (en) 2012-12-11
IL215788A0 (en) 2011-12-29
HUS2100022I1 (hu) 2021-07-28
US20190152990A1 (en) 2019-05-23
EP3045206A1 (fr) 2016-07-20
MX312216B (en) 2013-08-12
US9051337B2 (en) 2015-06-09
DK3284520T3 (da) 2019-09-16
US20170224694A1 (en) 2017-08-10
PL3045206T3 (pl) 2018-08-31
ES2667868T5 (es) 2023-06-01
IL186555A0 (en) 2008-01-20
US8129385B2 (en) 2012-03-06
IL225207A (en) 2017-11-30
IL225206A (en) 2017-11-30
KR20080009733A (ko) 2008-01-29
LT3372281T (lt) 2021-12-10
HUS2100023I1 (hu) 2021-07-28
MX302718B (es) 2012-08-27
US20160207939A1 (en) 2016-07-21
PT3045206T (pt) 2018-07-05
KR101363875B1 (ko) 2014-02-21
ES2446324T3 (es) 2014-03-07
EP3284519A8 (fr) 2018-04-18
US8410103B2 (en) 2013-04-02
EA200702080A1 (ru) 2008-04-28
MA29460B1 (fr) 2008-05-02
NO2017010I2 (no) 2017-03-27
SI1874117T1 (sl) 2014-01-31
BRPI0610030B1 (pt) 2020-09-15
DK3187225T3 (da) 2022-02-28
US20150232479A1 (en) 2015-08-20
US20130172559A1 (en) 2013-07-04
HUE044978T2 (hu) 2019-11-28
PT1874117E (pt) 2013-10-17
TW200716635A (en) 2007-05-01
NO20075165L (no) 2007-11-22
US20170253616A1 (en) 2017-09-07
LT3045206T (lt) 2018-06-11
US8778943B2 (en) 2014-07-15
US11267823B2 (en) 2022-03-08
CY2014024I1 (el) 2015-12-09
SI3284520T1 (sl) 2019-10-30
JP2008540343A (ja) 2008-11-20
FIC20210017I1 (fi) 2021-06-10
SI2465580T1 (sl) 2014-04-30
EP1874117B8 (fr) 2014-03-12
KR101848819B1 (ko) 2018-04-16
PL3372281T3 (pl) 2021-12-27
AU2006239177B2 (en) 2011-10-20
EP3187225B1 (fr) 2022-01-05
US20190284208A1 (en) 2019-09-19
NL301109I1 (nl) 2021-09-15
NO340111B1 (no) 2017-03-13
EP3372281A1 (fr) 2018-09-12
DK3372281T3 (da) 2021-09-27
HUE056603T2 (hu) 2022-02-28
NO2021018I1 (no) 2021-05-10
FR14C0041I1 (fr) 2014-06-27
AU2006239177A1 (en) 2006-11-02
EP1874117A1 (fr) 2008-01-09
WO2006116764A1 (fr) 2006-11-02
JP4295353B2 (ja) 2009-07-15
IL186555A (en) 2016-10-31
CY1115151T1 (el) 2015-12-09
SI3187225T1 (sl) 2022-04-29
BRPI0610030A2 (pt) 2011-10-11
LT3284520T (lt) 2019-09-25
JP2009079058A (ja) 2009-04-16
ES2906792T3 (es) 2022-04-20
ES2892304T3 (es) 2022-02-03
PL1874117T3 (pl) 2014-01-31
KR20140097438A (ko) 2014-08-06
CY1116331T1 (el) 2017-02-08
EP3045206B1 (fr) 2018-03-28
KR20130133061A (ko) 2013-12-05
PT2465580E (pt) 2014-02-25
HUS1400039I1 (hu) 2016-08-29
EP2465580A1 (fr) 2012-06-20
EP3372281B1 (fr) 2021-07-07
PT3372281T (pt) 2021-10-14
EP3187225A1 (fr) 2017-07-05
US20220213121A1 (en) 2022-07-07
US20170209454A1 (en) 2017-07-27
HK1172282A1 (en) 2013-04-19
US20170224695A1 (en) 2017-08-10
EP1874117A4 (fr) 2009-12-30
BRPI0610030B8 (pt) 2022-01-11
EA014162B1 (ru) 2010-10-29
US20090318421A1 (en) 2009-12-24
ES2743531T3 (es) 2020-02-19
US20200339598A1 (en) 2020-10-29
KR20160003889A (ko) 2016-01-11
HK1251191A1 (zh) 2019-01-25
EP3284520B1 (fr) 2019-06-05
US9273065B2 (en) 2016-03-01
NO339525B1 (no) 2016-12-27
US20170029438A1 (en) 2017-02-02
MX2007013351A (es) 2008-01-21
US10927129B2 (en) 2021-02-23
US20170369509A1 (en) 2017-12-28
US20120115875A1 (en) 2012-05-10
FR14C0041I2 (fr) 2015-11-13
NO2017010I1 (no) 2017-03-27
KR101504998B1 (ko) 2015-03-23
CA2606282C (fr) 2016-04-26

Similar Documents

Publication Publication Date Title
LU92446I2 (fr) Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium
LU93327I2 (fr) Opicapone ou un sel pharmaceutiquement acceptable de celui-ci
LU92568I2 (fr) Siméprévir, ou un sel de celui-ci, y compris le sodium siméprévir
LU92702I2 (fr) Naloxegol ou un sel pharmaceutiquement acceptable de celui-ci (moventig)
NO2023047I1 (no) Cedazuridine, or a pharmaceutically acceptable salt thereof
LU92137I2 (fr) Ruxolitinib, ou un de ses sels pharmaceutiquement acceptables
LU92883I2 (fr) Sonidégib ou un sel, hydrate ou solvate pharmaceutiquement acceptable qui en dérive
NO2020038I1 (no) Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt
LU93180I2 (fr) Alirocumab ou un dérivé pharmaceutiquement acceptable de celui-ci (PRALUENT)
FIC20240007I1 (fi) Gefapiksantti tai sen farmaseuttisesti hyväksyttävä suola
LU93312I2 (fr) Migalastat ou un sel de celui-ci, y compris le sel de chlorhydrate
NL301106I2 (nl) Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan
NO2019027I1 (no) kobicistat eller et farmasøytisk akseptabelt salt derav
NL301037I2 (nl) Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan
LU92785I2 (fr) Céritinib ou un sel pharamceutiquement acceptable de celui-ci
NL300703I2 (nl) Simeprevir, of een farmaceutisch aanvaardbaar zout daarvan, waaronder simeprevirnatrium.
NO2013008I2 (no) Krizotinib eller et farmasøytisk akseptabelt salt, hydrat eller solvat derav
LU92512I2 (fr) Afoxolaner, ou un oxyde nitrique de celui-ci, ou un sel pharmaceutiquement acceptable de celui-ci
NO2022022I1 (no) Fedratinib, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable hydrate thereof, in particular fedratinib dihydrochloride monohydrate
NO2016016I1 (no) Lesinurad, eller et farmasøytisk akseptabelt salt derav
LU91962I2 (fr) Azilsartan medoxomil (INN) et un de ses sels pharmaceutiquement acceptable, y compris le sel de potassium
MX2008007823A (en) Merocyanine derivatives
NL1031741A1 (nl) Purinederivaten.
NL2000627A1 (nl) Cycloalkylaminoderivaten.
IL190608A0 (en) 5-(arylsulfonyl)-pyrazolopiperidines